Japan based Astellas is slated to acquire Belgium based Ogeda for around €800 Mn ($849.08Mn). Under the agreement, Astellas will make an initial payment of €500Mn ($530.67 Mn) in consideration of 100% of the equity in Ogeda and an additional €300Mn ($318.41Mn) with attainment of certain clinical development and regulatory milestones for fezolinetant.
The closing of the transaction is subject to certain conditions and is expected to be finalized in the second quarter of 2017.
Astellas Pharma manufactures, markets, and imports/exports pharmaceutical products worldwide. The company offers Prograf, an immunosuppressant to prevent rejection in organ transplants; Vesicare, a treatment for overactive bladder; Protopic, a treatment for atopic dermatitis in the topical immunomodulator class; Harnal, a blocking agent to treat the functional symptoms of benign prostatic hyperplasia; and Funguard, a candin antifungal agent.
Astellas Pharma was founded in 1923 and is headquartered in Tokyo, Japan
Ogeda is a privately held preclinical-stage biopharmaceutical company based in Brussels Belgium. The company focuses on the discovery and development of small molecule drugs for unmet medical needs.
Source: – Astellas Pharma’s Press Release